Piedmont Cancer Institute – Locust Grove

Clinical Trials in Georgia

A Phase III, Multisite, Randomized, Double-Blind Trial of BNT327 in Combination With Chemotherapy Versus Placebo With Chemotherapy in Patients With Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC Determined Ineligible for PD(L)1 Therapy Based on PD-L1 Negative Disease
Cancer Type: Breast Cancer

A Randomized, Controlled, Multi-Center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared with Standard of Care in Patients with Early-Stage, Resectable Non-Small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations
Cancer Type: Lung Cancer

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (Krascendo 2)
Cancer Type: Lung Cancer

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Cancer Type: Colon/Rectal Cancer

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Cancer Type: Lung Cancer

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) (LIBRA)
Cancer Type: Lung Cancer

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients
Cancer Type: Lung Cancer, Unknown Primary

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Cancer Type: Cervical Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma

Pan-tumor MRD Study (Solid Tumor) - Observational Study
Cancer Type: Unspecified

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC = 50%) and Without Actionable Genomic Alterations
Cancer Type: Lung Cancer, Unknown Primary

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Cancer Type: Kidney Cancer, Unknown Primary

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Cancer Type: Urethral Cancer

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Cancer Type: Lung Cancer, Unknown Primary